K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
-
- B. Douglas Smith
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Yvette L. Kasamon
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Jeanne Kowalski
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Christopher Gocke
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Kathleen Murphy
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Carole B. Miller
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Elizabeth Garrett-Mayer
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Hua-Ling Tsai
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Lu Qin
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Christina Chia
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Barbara Biedrzycki
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Thomas C. Harding
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Guang Haun Tu
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Richard Jones
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Kristen Hege
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
-
- Hyam I. Levitsky
- Authors' Affiliations: 1Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
Description
<jats:title>Abstract</jats:title> <jats:p>Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia.</jats:p> <jats:p>Experimental Design: Patients with chronic phase CML who achieved at least a major cytogeneic response but remained with persistent, measurable disease despite one or more years on imatinib mesylate were eligible. Each was given a series of four vaccines administered in three-week intervals, with or without topical imiquimod, while remaining on a stable dose of imatinib mesylate. CML disease burden was measured serially before and after vaccination.</jats:p> <jats:p>Results: Nineteen patients were vaccinated, with a median duration of previous imatinib mesylate therapy of 37 (13–53) months. Mean PCR measurements of BCR-ABL for the group declined significantly following the vaccines (P = 0.03). Thirteen patients had a progressive decline in disease burden, 8 of whom had increasing disease burden before vaccination. Twelve patients achieved their lowest tumor burden measurements to date following vaccine, including seven subjects who became PCR-undetectable.</jats:p> <jats:p>Conclusions: K562/GM-CSF vaccine appears to improve molecular responses in patients on imatinib mesylate, including achieving complete molecular remissions, despite long durations of previous imatinib mesylate therapy. Clin Cancer Res; 16(1); 338–47</jats:p>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 16 (1), 338-347, 2010-01-01
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1362825893436515584
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref